L3Harris Technologies 株価情報 (NYSE: LHX)

最新ニュース L3Harris Technologies (NYSE:LHX) 株価情報

L3HARRIS TECHNOLOGIES INC

L3Harris Technologies

L3Harris Technologies provides products primarily for the command, control, communications, computers, intelligence, surveillance, and reconnaissance, or C4ISR, market. The firm produces uncrewed aerial vehicles, sensors, and avionics, provides military and commercial training services, and maintains the us Federal Aviation Administration's communications infrastructure. In July 2023, the company acquired Aerojet Rocketdyne, a key supplier of rocket motors used in the space industry and to propel munitions.

L3Harris Technologies Inc

News

Intchains Group Announced It Has Entered Into A Securities Purchase Agreement With An Institutional Investor For A Registered Direct Offering Of 361,011 Of Its American Depositary Shares, Each ADS Representing Two Class A Ordinary Shares Of The Company At $2.77 Per ADS

For the fiscal full year 2026, SailPoint expects:
<ul>
<li>Total ARR: In the range of $1,075 to $1,085 million, representing 23% to 24% year-over-year growth.</li>
<li>Total Revenue: In the range of $1,025 to $1,035 million, representing 19% to 20% year-over-year growth.</li>
<li>Adjusted Income from Operations: In the range of $151 to $156 million, representing adjusted operating margin of 14.6% to 15.2%.</li>
<li>Adjusted EPS: In the range of $0.14 to $0.18 per diluted share.</li>
</ul>

Guidance

SAIL

SailPoint Expects FY25 Revenue Of $1.025B-$1.035B Vs $1.023B Est, Adjusted EPS Of $0.14-$0.18 Vs $0.13 Est

Contracts

Gasboy, A Vontier Company Announced That It Has Secured A Coveted Sourcewell Contract Alongside Vontier Portfolio Partners Angi, Teletrac Navman, Veeder-root And Konect

LSPD

Lightspeed  Sees Gross Profit CAGR Of ~20-25% And Customer Location CAGR Of ~10-15% In Its Two Growth Engines - Retail In North America And Hospitality In Europe For The Next Three Years

On Tuesday, March 25, U.S. markets closed in green as investors reacted to mixed signals: Apple gained while Nvidia dipped, and attention turned to possible shifts in Trump&#8217;s trade policy.
Market uncertainty persists amid inflation worries, declining fiscal strength, and cautious Fed comments. The key focus now shifts to Friday&#8217;s release of the Fed&#8217;s preferred inflation gauge, the PCE index.
In economic data, Consumer confidence dipped to 92.9, missing expectations of 93.5. Home prices rose 4.7% in January, slightly below forecasts of 4.8% but higher than December&#8217;s 4.5%. New home sales climbed 1.8% to 676,000 in February, falling short of the 680,000 estimate, despite rebounding from January&#8217;s revised 6.9% drop, suggesting lingering housing market uncertainty.
Most S&amp;P 500 sectors rose, led by consumer discretionary, communication, and financial stocks, while utilities and health care declined.
The Dow Jones Industrial Average increased by 0.01% to 42,587.50, the S&amp;P 500 up 0.16% to 5,776.65, and the Nasdaq Composite rose 0.47% to 18,271.86.
Asia Markets Today
<ul>
<li>On Wednesday, Japan&#8217;s Nikkei 225 closed the session higher by 0.73% at 38,057.00, led by gains in the Power, Rubber and Chemical, Petroleum &amp; Plastic sectors.</li>
<li>Australia&#8217;s S&amp;P/ASX 200 was up 0.71% and closed at 7,999.00, led by gains in the A-REITs, Consumer Staples, and Industrials sectors.</li>
<li>India&#8217;s Nifty 50 fell 0.77% to 23,486.85, while Nifty 500 was down 0.76% at 21,275.45.</li>
<li>China&#8217;s Shanghai Composite declined 0.04% to 3,368.70, and the Shanghai Shenzhen CSI 300 rose   0.51% to 3,934.85.</li>
<li>Hong Kong&#8217;s Hang Seng was up 0.60%, ending the session at 23,483.32.</li>
</ul>
Eurozone at 06:00 AM ET
<ul>
<li>The European STOXX 50 was down 0.96%.</li>
<li>Germany&#8217;s DAX declined 0.95%.</li>
<li>France&#8217;s CAC slid 0.92%.</li>
<li>U.K.&#8217;s FTSE 100 index traded higher by 0.03%.</li>
<li>European shares fell as healthcare stocks dragged the STOXX 600 lower despite gains in energy. Caution lingered over U.S. tariffs, though Europe remains attractive amid German stimulus hopes.       </li>
</ul>
Commodities at 06:00 AM ET
<ul>
<li>Crude Oil WTI was trading higher by 0.62% at $69.43/bbl, and Brent was up 0.62% at $72.84/bbl.</li>
<li>Oil prices rose slightly on tighter supply fears after a U.S. tariff threat on Venezuelan crude buyers and a surprise U.S. inventory drop, though gains were capped by easing tensions between Russia and Ukraine.</li>
<li>Natural Gas gained 0.39% to $3.982.</li>
<li>Gold was trading lower by 0.09% at $3,051.95, Silver was up 0.17% to $34.248, and Copper gained 1.27% to $5.2770.</li>
</ul>
U.S. Futures at 06:00 AM ET
<ul>
<li>Dow futures were down 0.15%, S&amp;P 500 futures declined 0.18% and Nasdaq 100 futures slid 0.24%.</li>
<li>U.S. stock futures dipped Wednesday as investors awaited clarity on Trump&#8217;s upcoming tariff measures, set for April 2.</li>
</ul>
Forex at 06:00 AM ET
The U.S. Dollar Index slid 0.01% to 104.20, USD/JPY was up 0.10% to 150.04, and USD/AUD declined 0.138% to 1.5804.
Photo by Pavel Bobrovskiy via Shutterstock

Asia

Emerging Markets

Eurozone

Futures

Commodities

Forex

Markets

ADIV

AGOV

ASHR

BBEU

BOIL

CQQQ

PowerShares DBmmodity Index Optimum Yield Diversified Fund

EEMA

FLAX

CurrencyShares British Pound Sterling Trust

IEMG

IEUR

KraneShares Trust KraneShares S&P Pan Asia Dividend Aristocrats Index ETF

KDIV

SPEM

USDU

PowerShares DB US Dollar Index Bullish Fund

Asia Markets Mixed, Europe Down As Tariff Concerns Persist - Global Markets Today While US Slept

DLTR

Dollar Tree Sees Q1 Comparable Store Sales Growth Of 3% - 5%

Biotech

General

VKTX

Viking Therapeutics Completes Enrollment In Phase 2 VENTURE-Oral Dosing Trial Of VK2735 Tablet Formulation For Patients With Obesity

U.S. stock futures were lower this morning, with the Dow futures falling around 50 points on Wednesday.
Shares of Chewy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>) fell sharply in pre-market trading after the company reported quarterly <a href="https://in.benzinga.com/25/03/44476959/chewy-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call">earnings</a>.
Chewy reported quarterly earnings of 28 cents per share which beat the analyst consensus estimate of 5 cents per share. The company reported quarterly sales of $3.25 billion which beat the analyst consensus estimate of $3.20 billion, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Chewy shares declined 3.5% to $32.44 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Humacyte, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUMA#NASDAQ">HUMA</a>) shares fell 22.1% to $2.24 in pre-market trading after the company priced its $50 million public offering of 25 million common stock at $2.00 per share.</li>
<li>Zhengye Biotechnology Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYBT#NASDAQ">ZYBT</a>) shares tumbled 14.6% to $7.00 in pre-market trading after gaining 41% on Tuesday.</li>
<li>Nyxoah S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NYXH#NASDAQ">NYXH</a>) fell 11.8% to $9.99 in today's pre-market trading. The FDA issued Nyxoah an approvable letter for its Genio&#xAE; system.</li>
<li>Rapport Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAPP#NASDAQ">RAPP</a>) fell 9.5% to $9.10 in pre-market trading.</li>
<li>Oruka Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORKA#NASDAQ">ORKA</a>) shares fell 5% to $11.40 in pre-market trading.</li>
<li>REGENXBIO Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGNX#NASDAQ">RGNX</a>) fell 3.8% to $7.90 in pre-market trading.</li>
<li>Rapport Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAPP#NASDAQ">RAPP</a>) declined 3.5% to $9.70 in pre-market trading.</li>
<li>Perpetua Resources Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPTA#NASDAQ">PPTA</a>) fell 3% to $10.87 in pre-market trading.</li>
<li>Bausch Health Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHC#NYSE">BHC</a>) slipped 2.4% to $6.83 in pre-market trading. Bausch Health announced the pricing of upsized private offering of senior secured notes.</li>
</ul>
Now Read This:
<ul>
<li> <a href="https://www.benzinga.com/25/03/44471817/top-2-health-care-stocks-that-are-ticking-portfolio-bombs-3">Top 2 Health Care Stocks That Are Ticking Portfolio Bombs</a></li>
</ul>

Pre-Market Outlook

Movers

Trading Ideas

CHWY

HUMA

NYXH

ORKA

PPTA

RAPP

RGNX

ZYBT

Chewy, Bausch Health Companies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Dollar Tree Sees Q1 Revenue Of $4.5B - $4.6B; Adj EPS Of $1.10 - $1.25

Needham analyst Serge Belanger maintains Cormedix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) with a Buy and lowers the price target from $18 to $12.

Price Target

Analyst Ratings

CRMD

Needham Maintains Buy on Cormedix, Lowers Price Target to $12

Chewy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>) reported quarterly earnings of $0.28 per share which beat the analyst consensus estimate of $0.05 by 460 percent. This is a 55.56 percent increase over earnings of $0.18 per share from the same period last year. The company reported quarterly sales of $3.25 billion which beat the analyst consensus estimate of $3.20 billion by 1.53 percent. This is a 14.75 percent increase over sales of $2.83 billion the same period last year.

Earnings

Chewy Q4 2024 Adj EPS $0.28 May Not Be Comparable To $0.05 Estimate, Sales $3.25B Beat $3.20B Estimate

RILY

B. Riley Financial Announced It Has Entered Into A Privately Negotiated Exchange Agreement With An Institutional Investor, Which Will Reduce The Company's Total Outstanding Debt By Approximately $35M

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Arvinas Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARVN#NASDAQ">ARVN</a>)</h3>
<ul>
<li>On March 11, Arvinas announced topline results from the phase 3 VERITAC-2 Trial of Vepdegestrant Monotherapy versus Fulvestrant in adults with advanced or retastatic breast cancer. The company's stock fell around 53% over the past month and has a <a href="https://www.benzinga.com/quote/ARVN">52-week low of $7.91</a>.</li>
<li>RSI Value: 25.9</li>
<li>ARVN Price Action: Shares of Arvinas fell 5.6% to close at $8.13 on <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Tuesday</a>. </li>
</ul>
<h3 class="wp-block-heading">Simulations Plus Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul>
<li>Simulations Plus will report second quarter fiscal 2025 financial results after the market close on Thursday, April 3. The company's stock fell around 19% over the past month and <a href="https://www.benzinga.com/quote/SLP">has a 52-week low </a>of $24.00.</li>
<li>RSI Value: 29.7</li>
<li>SLP Price Action: Shares of Simulations Plus fell 3.2% to close at $24.72 on Tuesday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">SLP stock</a>. </li>
</ul>
<h3 class="wp-block-heading">Iovance Biotherapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOVA#NASDAQ">IOVA</a>)</h3>
<ul>
<li>On March 21, Iovance Biotherapeutics reported inducement grants under NASDAQ listing rule 5635(c)(4). The company's stock fell around 35% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/IOVA">low of $3.42.</a></li>
<li>RSI Value: 26.7</li>
<li>IOVA Price Action: Shares of Iovance Biotherapeutics fell 4.1% to close at $3.48 on Tuesday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">IOVA shares</a>. </li>
</ul>
Learn more about BZ Edge Rankings—<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound" target="_blank" rel="noreferrer noopener">click to see scores for other stocks in the sector and see how they compare.</a> 
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44471817/top-2-health-care-stocks-that-are-ticking-portfolio-bombs-3">Top 2 Health Care Stocks That Are Ticking Portfolio Bombs</a></li>
</ul>

Long Ideas

ARVN

IOVA

Top 3 Health Care Stocks That Are Set To Fly This Month

Financial Outlook
For the first quarter of fiscal 2026, SailPoint expects:
<ul>
<li>Total ARR: In the range of $896 to $900 million, representing 26% to 27% year-over-year growth.</li>
<li>Total Revenue: In the range of $224 to $226 million, representing 19% to 20% year-over-year growth.</li>
<li>Adjusted Income from Operations: In the range of $14 to $15 million, representing adjusted operating margin of 6.2% to 6.7%.</li>
<li>Adjusted EPS: In the range of ($0.02) to $0.00 per diluted share.</li>
</ul>
For the fiscal full year 2026, SailPoint expects:
<ul>
<li>Total ARR: In the range of $1,075 to $1,085 million, representing 23% to 24% year-over-year growth.</li>
<li>Total Revenue: In the range of $1,025 to $1,035 million, representing 19% to 20% year-over-year growth.</li>
<li>Adjusted Income from Operations: In the range of $151 to $156 million, representing adjusted operating margin of 14.6% to 15.2%.</li>
<li>Adjusted EPS: In the range of $0.14 to $0.18 per diluted share.</li>
</ul>

SailPoint Expects Q1 Revenue Of $224M-$226M Vs $228.43M Est, Adjusted EPS Of $(0.02)-$0.00 Vs $(0.01) Est

GME: 14% &#x7C; <a href="https://www.benzinga.com//node/44481286">GameStop shares are trading higher following better-than-expected Q4 adjusted EPS results.</a>
&nbsp;
DLTR: 7% &#x7C; <a href="https://www.benzinga.com//node/44480520">Dollar Tree shares are trading lower after Truist Securities cut its price target on the stock from $83 to $76.</a>
&nbsp;
SURG: 114% &#x7C; <a href="https://www.benzinga.com//node/44481687">SurgePays shares are trading higher after the company reported better-than-expected FY24 sales results.</a>

SURG

Market-Moving News for March 26th

The ADOPT study concluded in February 2025 and evaluated HealthVCF at four National Health Services (NHS) trusts: Cambridge, Bradford, Cardiff and Southampton – coordinated by the long-standing clinical users at Oxford. In earlier findings from the ADOPT study, HealthVCF analyzed 37,220 routine medical CT scans and identified over 3,450 new patients with vertebral compression fractures, up to six times more than the national average at NHS hospitals in the UK. These patients were asymptomatic, and the early data underscores the importance of addressing the critical gap in detection of patients with vertebral fractures.

NNOX

Nanox To Showcase AI Bone Health Data Across Four Major European Medical Conferences Through June 2025

This partnership enables the two companies to support the continued reshoring of domestic supply chains for the U.S. solar industry.

FSLR

SHLS

Shoals Technologies Reveals Continued Commitment To Investment In Domestic Manufacturing In Alabama With First Solar

ECVT

Ecovyst And Enzyme Supplies Announce The Signing Of A Memorandum Of Understanding Focused On Accelerating The Growth Of Enzyme Immobilization Technologies

Dollar Tree Sees FY25 Comparable Store Sale Growth Of 3% - 5%

Dollar Tree Sees FY25 Sales Of $18.5B - $19.1B; Adj EPS of $5.00 - $5.50

Press Releases

US Air Force Completes First Flight of L3Harris Viper Shield Electronic Warfare System

L3Harris Launches New Technology to Control Autonomous Swarms

L3Harris to Present at Upcoming Investor Conference

Integration of Emerging Technologies for Military Drone Market Presenting a Significant Growth Opportunity

L3Harris Breaks Ground on Solid Rocket Motor 'Factories of the Future' in Arkansas

Shield AI and L3Harris Team for Breakthrough in Autonomy

MAXAR SPACE SYSTEMS Successfully Delivers Tranche 1 Tracking Layer Spacecraft to L3Harris

L3Harris Announces Quarterly Dividend Increase

Development of Global Drone Operational Integration Expected to Spur Investment for U.S. Drone Manufacturing

Shield AI raises $240M at $5.3B valuation to scale Hivemind Enterprise, an AI-powered autonomy developer platform

Comments

L3Harris Technologies

ニュース

最新ニュース L3Harris Technologies (NYSE:LHX) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル